Beardwell C G, Hindley A C, Wilkinson P M, Todd I D, Ribeiro G G, Bu'Lock D
Cancer Chemother Pharmacol. 1983;10(3):158-60. doi: 10.1007/BF00255752.
The combination of trilostane 960 mg daily and either dexamethasone 0.5 mg b.d. or hydrocortisone 10 mg b.d. has been used to treat advanced metastatic breast cancer in post-menopausal women. Twenty-three patients had assessable disease and received treatment for a minimum of 8 weeks. Six (26%) showed an objective response and three (13%), stabilisation of previously progressive disease, sustained for at least 3 months. Side-effects were mainly gastrointestinal. Biochemical studies suggest that the mechanism of action may be inhibition of conversion of androstenedione to oestrone.
每日服用960毫克曲洛司坦并联合0.5毫克地塞米松每日两次或10毫克氢化可的松每日两次，已被用于治疗绝经后女性的晚期转移性乳腺癌。23例患者有可评估的疾病，并接受了至少8周的治疗。6例（26%）显示出客观缓解，3例（13%）之前进展性疾病稳定，且持续至少3个月。副作用主要是胃肠道方面的。生化研究表明，其作用机制可能是抑制雄烯二酮向雌酮的转化。
Zotero 插件